Significance of GPRC5D as a Target for R/R MM
A panel of experts on multiple myeloma discuss the importance of GPRC5D as a target of interest in relapsed/refractory disease and discuss their experiences with talquetamab in clinical practice.
Now Viewing
EP: 1.Significance of GPRC5D as a Target for R/R MM
EP: 2.Long-Term Follow-Up of MonumenTAL-1
EP: 3.MonumenTAL-1: Efficacy and Safety Data
EP: 4.Broader Implications and Current Trials of GPRC5D-Targeted Treatments in Relapsed/Refractory Multiple Myeloma
EP: 5.Overview of MonumenTAL-2 and MonumenTAL-3
EP: 6.Evaluating Combination Strategies in R/R MM: TRIMM-2, TRIMM-3, MajesTEC-3
EP: 7.Exploring GPRC5D as an Important Target for Multiple Myeloma
EP: 8.Overview of RedirecTT-1, MagnetisMM-30 and MagnetisMM-5
EP: 9.Implications of Combination Regimens for R/R MM
EP: 10.Overview of Recent Updates in Bispecific Therapy in R/R MM
EP: 11.Impact of T-cell Affinity in Bispecific Therapy in R/R MM
Video content above is prompted by the following:
- Why is GPRC5D is a target of interest in relapsed/refractory multiple myeloma?
- Have you had experience using talquetamab in your practice?
Recent Videos
Related Content
